NEW YORK (GenomeWeb) – Canaccord Genuity has upgraded its rating for Genomic Health to Buy from Hold, the investment banking company said today.

After surveying and interviewing urologists, Canaccord analyst Mark Massaro wrote in his note, the bank found that Genomic Health has the best brand awareness for its cancer tests. "To our surprise, more docs responded they are aware of GHDX's test over MYGN's test, despite MYGN's first mover advantage, which we think is a testament to GHDX's solid early marketing and commercial initiatives," he added.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.